NetworkNewsBreaks – Revance Therapeutics, Inc. (NASDAQ: RVNC) Featured in Mizuho Securities Research Report
Revance Therapeutics (NASDAQ: RVNC) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Revance released positive topline Phase 3 data for their neurotoxin Daxi in the treatment of cervical dystonia (CD) today. While investors remain predominantly focused on the Nov 25 FDA Action Date for Daxi in aesthetics, this morning's data confirms Daxi's ability to play a role on the therapeutics side, with CD the first of potentially multiple therapeutic indications where a longer-lasting toxin could have an important role. We reiterate our Buy rating and $32 PT on RVNC shares.” To…







